Ambrogio F, Martella LA, Odetti P, Monacelli F (2019) Behavioral disturbances in dementia and beyond: time for a new conceptual frame? Int J Mole Sci 20(15):3647. https://doi.org/10.3390/2Fijms20153647

Article  CAS  Google Scholar 

American Psychiatric Association. (2022). Diagnostic and statistical manual of mental disorders (5th ed., text rev.). https://doi.org/10.1176/appi.books.9780890425787

*Bulbena-Cabré A, Bulbena A (2016) Aripiprazole-induced hypersexuality.Primary Care Companion CNS Disorders 18(6): 26650https://doi.org/10.4088/pcc.16l01983

Burk BG, DiGiacomo T, Polancich S, Pruett BS, Sivaraman S, Birur B (2023) Antipsychotics and obsessive–compulsive disorder/obsessive–compulsive symptoms: A pharmacovigilance study of the FDA adverse event reporting system. Acta Psychiatr Scand. https://doi.org/10.1111/acps.13567

Article  PubMed  Google Scholar 

*Ceylan ME, Evrensel A, Ünsalver BÖ, Cömert G (2021) Pathological gambling due to aripiprazole: two cases. West Indian Med J69(3): 154-156https://doi.org/10.7727/wimj.2015.107

*Chen HY, Ma CH, Liu CC (2019) Two cases of de novo pathological gambling associated with aripiprazole. Clin Neuropharmacol 42(3): 101-102https://doi.org/10.1097/wnf.0000000000000342

*Cheon E, Koo BH, Seo SS, Lee JY (2013) Two cases of hypersexuality probably associated with aripiprazole. Psychiatry Inv 10(2): 200https://doi.org/10.4306/pi.2013.10.2.200

*Çildir DA, Kalyoncu T (2018) Trichotillomania associated with aripiprazole: a case report. J Clin Psychopharmacol 38(1): 98-99https://doi.org/10.1097/jcp.0000000000000821

*Cohen J, Magalon D, Boyer L, Simon N, Lançon C (2011) Aripiprazole-induced pathological gambling: a report of 3 cases. Curr Drug Saf 6(1):51-53https://doi.org/10.2174/157488611794480016

*Corbeil O, Corbeil S, Giroux I, Jacques C, Dorval M, Demers MF, Roy MA (2020) Problem gambling associated with aripiprazole in first-episode psychosis patients: a series of 6 case reports. J Clin Psychopharmacol 40(2):191-194https://doi.org/10.1007/s40263-021-00801-4

Cox JH, Cavanna AE (2021) Aripiprazole for the treatment of Tourette syndrome. Expert Rev Neurotherapeut 21(4):381–391. https://doi.org/10.4088/2Fpcc.v07n0605

Article  CAS  Google Scholar 

*Das S, Chatterjee SS, Bagewadi V (2017) Aripiprazole induced hypersexuality, when we should be cautious? Asian J Psychiatry 29:162-163https://doi.org/10.1016/j.ajp.2017.05.023

De Micco R, Satolli S, Siciliano M, De Mase A, Giordano A, Tedeschi G, Tessitore A (2022) Effects of safinamide on non-motor, cognitive, and behavioral symptoms in fluctuating Parkinson’s disease patients: a prospective longitudinal study. Neurol Sci 43(1):357–364. https://doi.org/10.1007/s10072-021-05324-w

Article  PubMed  Google Scholar 

Derakhshanpour F, Deylamsalehi A, Moghadda SSJ, Shahini N (2022) Efficacy of aripiprazole and risperidone in treatment of children with attention-deficit/hyperactivity disorder: a double-blind clinical trial study. Bull Pharmaceut Sci Assiut 45(1):281–288. https://doi.org/10.21608/bfsa.2022.239464

Article  Google Scholar 

*Desarkar P, Das A, Nizamie SH (2007) Aripiprazole-induced obsessive-compulsive disorder: a report of 2 cases. J Clin Psychopharmacol 27(3): 305-306https://doi.org/10.1097/01.jcp.0000270091.32286.0a

*Dhillon R, Bastiampillai T, Cao CZ, Eckert TG, Tibrewal P (2017) Aripiprazole and impulse-control disorders: a recent FDA warning and a case report. Primary Care Companion for CNS Disorders19(1): 26647https://doi.org/10.4088/pcc.16l02003

Dold M, Aigner M, Lanzenberger R, Kasper S (2015) Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: an update meta-analysis of double-blind, randomized, placebo-controlled trials. Int J Neuropsychopharmacol 18(9):pyv047. https://doi.org/10.1093/ijnp/pyv047

Article  CAS  PubMed  PubMed Central  Google Scholar 

Doval N, Das S, Moun V (2017) Aripiprazole in tardive dyskinesia: is it a safe choice? J Neurosci Rural Practice 8(02):294–295. https://doi.org/10.4103/jnrp.jnrp_359_16

Article  Google Scholar 

Downing L, Kim DD, Procyshyn RM, Tibbo P (2019) Management of sexual adverse effects induced by atypical antipsychotic medication. J Psychiatry Neurosci 44(4):287–288. https://doi.org/10.1503/2Fjpn.190053

Article  PubMed  PubMed Central  Google Scholar 

Endomba FT, Tankeu AT, Nkeck JR, Tochie JN (2020) Leptin and psychiatric illnesses: Does leptin play a role in antipsychotic-induced weight gain? Lipids Health Dis 19:1–12. https://doi.org/10.1186/s12944-020-01203-z

Article  Google Scholar 

Faheem M, Akram W, Akram H, Khan MA, Siddiqui FA, Majeed I (2022) Gender-Based Differences in Prevalence and Effects of ADHD in Adults; a Systematic Review. Asian J Psychiatry 103205. https://doi.org/10.1016/j.ajp.2022.103205

Ferrari E, Fraschini F, Brambilla F (1990) Hormonal circadian rhythms in eating disorders. Biol Psychiat 27(9):1007–1020. https://doi.org/10.1016/0006-3223(90)90037-3

Article  CAS  PubMed  Google Scholar 

Furukawa Y, Hamza T, Cipriani A, Furukawa TA, Salanti G, Ostinelli EG (2022) Optimal dose of aripiprazole for augmentation therapy of antidepressant-refractory depression: Preliminary findings based on a systematic review and dose–effect meta-analysis. Br J Psychiatry 221(2):440–447. https://doi.org/10.1192/bjp.2021.165

Article  PubMed  Google Scholar 

Fusaroli M, Giunchi V, Battini V, Gringeri M, Rimondini R, Menchetti M, Poluzzi E (2023) Exploring the underlying mechanisms of drug-induced impulse control disorders: a pharmacovigilance-pharmacodynamic study. Psychiatry Clin Neurosci 77(3):160–167. https://doi.org/10.1111/pcn.13511

Article  CAS  PubMed  Google Scholar 

*Gaboriau L, Victorri-Vigneau C, Gérardin M, Allain-Veyrac G, Jolliet-Evin P, Grall-Bronnec M (2014) Aripiprazole: a new risk factor for pathological gambling? A report of 8 case reports. Addictive Behaviors 39(3) 562-565https://doi.org/10.1016/j.addbeh.2013.11.005

*Gavaudan G, Magalon D, Cohen J, Lançon C, Léonetti G, Pélissier‐Alicot AL (2010) Partial agonist therapy in schizophrenia: relevance to diminished criminal responsibility. J Forensic Sci 55(6):659-1662https://doi.org/10.1111/j.1556-4029.2010.01483.x

Giri YR, Peteru SR (2019) Escalation of gambling associated with aripiprazole: a case report and literature review. J Psychiatric Practice® 25(2):139–145. https://doi.org/10.1097/pra.0000000000000367

Article  PubMed  Google Scholar 

Goh CMJ, Asharani PV, Abdin E, Shahwan S, Zhang Y, Sambasivam R,... Subramaniam M (2022) Gender differences in alcohol use: a nationwide study in a multiethnic population. Int J Mental Health Addict 1–15. https://doi.org/10.1007/s11469-022-00921-y

*Golouh V, Celofiga A (2021) Pathological Gambling and Compulsive Eating Associated with Long-Acting Injectable Aripiprazole: A Case Report. Psychiatria Danubina 33(3):373–375. https://doi.org/10.24869/psyd.2021.373

Guo K, Feng Z, Chen S, Yan Z, Jiao Z, Feng D (2022) Safety profile of antipsychotic drugs: analysis based on a provincial spontaneous reporting systems Database. Front Pharmacol 13:848472. https://doi.org/10.3389/fphar.2022.848472

Article  CAS  PubMed  PubMed Central  Google Scholar 

*Gupta P, Gupta R, Balhara YPS (2017) Obsessive-compulsive symptoms associated with aripiprazole treatment in bipolar disorder: a case report. J Clin Psychopharmacol 37(1):108 109https://doi.org/10.1097/jcp.0000000000000629

Hattori S, Suda A, Kishida I, Miyauchi M, Shiraishi Y, Noguchi N, Hishimoto A (2023) Differences in autonomic nervous system activity between long-acting injectable aripiprazole and oral aripiprazole in schizophrenia. BMC Psychiatry 23(1):1–7. https://doi.org/10.1186/s12888-023-04617-y

Article  Google Scholar 

Hing N, Russell A, Tolchard B, Nower L (2016) Risk factors for gambling problems: An analysis by gender. J Gambl Stud 32:511–534. https://doi.org/10.1007/s10899-015-9548-8

Article  PubMed  Google Scholar 

IBM Corp. Released 2019. IBM SPSS Statistics for Windows, Version 26.0. Armonk, NY: IBM Corp

Ichikawa J, Li Z, Dai J, Meltzer HY (2002) Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism. Brain Res 956(2):349–357. https://doi.org/10.1016/S0006-8993(02)03570-9

Article  CAS  PubMed  Google Scholar 

Johnson J, El-Alfy AT (2016) Review of available studies of the neurobiology and pharmacotherapeutic management of trichotillomania. J Adv Res 7(2):169–184. https://doi.org/10.1016/j.jare.2015.05.001

Article  CAS  PubMed  Google Scholar 

*Jones R, Shad M (20190 Aripiprazole-induced kleptomania: Case report. J Affect Disord 244: 242 243https://doi.org/10.1016/j.jad.2018.05.042

Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW (2002) Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 63(9):763–771. https://doi.org/10.4088/jcp.v63n0903

Article  CAS  PubMed  Google Scholar 

Kikuchi T, Maeda K, Suzuki M, Hirose T, Futamura T, McQuade RD (2021) Discovery research and development history of the dopamine D2 receptor partial agonists, aripiprazole and brexpiprazole. Neuropsychopharmacology Reports 41(2):134–143. https://doi.org/10.1002/2Fnpr2.12180

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim SW, Shin IS, Kim JM, Youn T, Yang SJ, Hwang MY, Yoon JS (2009) The 5-HT2 receptor profiles of antipsychotics in the pathogenesis of obsessive-compulsive symptoms in schizophrenia. Clin Neuropharmacol 32(4): 224 226https://doi.org/10.1097/wnf.0b013e318184fafd

Kneller LA, Zubiaur P, Koller D, Abad-Santos F, Hempel G (2021) Influence of CYP2D6 phenotypes on the pharmacokinetics of aripiprazole and dehydro-aripiprazole using a physiologically based pharmacokinetic approach. Clinical Pharmacokinetics 60(12):1569–1582. https://doi.org/10.1007/2Fs40262-021-01041-x

Article  CAS  PubMed  PubMed Central  Google Scholar 

*Kobayashi N, Takano M (2018) Aripiprazole-induced sleep-related eating disorder: a case report. J Med Case Reports 12(1):1-4https://doi.org/10.1186/s13256-018-1622-2

Kodama M, Hamamura T (2010) Aripiprazole-induced behavioural disturbance related to impulse control in a clinical setting. Int J Neuropsychopharmacol 13(4):549 551https://doi.org/10.1017/S1461145709990976

Kopelman JM (2020) The role of Slc1a1 in OCD-relevant behavior and associated neural activity (Doctoral dissertation, University of Pittsburgh). 30163899

Kozian R (2019) Hypersexuality induced by aripiprazole. Psychiatr Prax 47(1):43–45. https://doi.org/10.1055/a-0941-3874

Article  PubMed  Google Scholar 

Lachance A, Corbeil O, Corbeil S, Chalifour G, Breault AS, Roy MA, Demers MF (2019) Case reports of aripiprazole and problematic gambling in schizophrenia: a critical review of the evidence. J Clin Psychopharmacol 39(4):393–397. https://doi.org/10.1097/JCP.0000000000001068

Article  PubMed  Google Scholar 

Lamy M, Erickson CA (2018) Pharmacological management of behavioral disturbances in children and adolescents with autism spectrum disorders. Curr Probl Pediatr Adolesc Health Care 48(10):250–264. https://doi.org/10.1016/j.cppeds.2018.08.015

Article  PubMed  Google Scholar 

Li P, Snyder GL, Vanover EK (2016) Dopamine targeting drugs for the treatment of schizophrenia: past, present and future. Curr Topics Med Chem 16(29):3385–3403. https://doi.org/10.2174/2F1568026616666160608084834

Article  CAS  Google Scholar 

*Lin C, Chang HM, Huang MC (2020) Aripiprazole-induced obsessive-compulsive symptoms. Taiwanese J Psychiatry 34 1 47https://doi.org/10.4103/TPSY.TPSY_34_19

Martinotti G, Orsolini L, Fornaro M, Vecchiotti R, De Berardis D, Iasevoli F, Di Giannantonio M (2016) Aripiprazole for relapse prevention and craving in alcohol use disorder: current evidence and future perspectives. Expert Opinion Inv Drugs 25(6):719–728. https://doi.org/10.1080/13543784.2016.1175431

Article  CAS  Google Scholar 

Mathes BM, Morabito DM, Schmidt NB (2019) Epidemiological and clinical gender differences in OCD. Curr Psychiatry Rep 21:1–7. https://doi.org/10.1007/s11920-019-1015-2

Article  Google Scholar 

McIntyre RS, Such P, Yildirim M, Madera JM, Zhang Z, Larsen F, Harlin M (2023) Safety and efficacy of aripiprazole 2-month ready-to-use 960 mg: secondary analysis of outcomes in adult patients with bipolar I disorder in a randomized, open-label, parallel-arm, pivotal study. Curr Med Res Opinion, (just-accepted) 39:1–16. https://doi.org/10.1080/03007995.2023.2219155

Article  CAS  Google Scholar 

Merino D, Gérard AO, Van Obberghen EK, Ben Othman N, Ettore E, Giordana B, Drici MD (2022) Medications as a trigger of sleep-related eatin